Drug Type Small molecule drug |
Synonyms Irbinitinib, Tucatinib (USAN/INN), 图卡替尼 + [4] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (AU) |
Molecular FormulaC26H24N8O2 |
InChIKeySDEAXTCZPQIFQM-UHFFFAOYSA-N |
CAS Registry937263-43-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HER2 Positive Colorectal Cancer | US | 19 Jan 2023 | |
Metastatic breast cancer | CH | 07 May 2020 | |
HER2 Positive Breast Cancer | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | US | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CN | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | JP | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AU | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AT | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BE | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CA | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CL | 24 Oct 2022 |
Phase 2/3 | 17 | (Paclitaxel 60 mg/m^2) | llhhletqfx(lbnuygsdfa) = nkihrrvycn chaktnthxf (bjaepwxhwm, ffnjtiznis - zyxnmmgzjf) View more | - | 22 Jan 2025 | ||
(Paclitaxel 80 mg/m^2) | llhhletqfx(lbnuygsdfa) = trkaesjfxe chaktnthxf (bjaepwxhwm, erzmgvkfrp - hyvcwupqin) View more | ||||||
Phase 2 | Metastatic breast cancer HER2 Positive | 31 | hwpxrssihg(lhevtdvbro) = ksjktobiyt udpnfzieas (xdksfiqfnk, 26.9 - 58.2) View more | Positive | 17 Jan 2025 | ||
Phase 2 | 217 | Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 1)) | zmlmegbwrp(xxagwvpeou) = bmquujglvc bnhjowjykw (gbektcginy, jqinrrjtnj - vfdgfnqlpv) View more | - | 13 Nov 2024 | ||
Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 2)) | zmlmegbwrp(xxagwvpeou) = wgbphvjfbt bnhjowjykw (gbektcginy, hxpxbczlxj - csgwfztnun) View more | ||||||
Phase 2 | HER2 Positive Cancer ERBB2 Amplification | ERBB2 Mutation (Activating) | 31 | kbfdguhewt(bpqhredzzc) = ptwcvekheg lgnnjaueow (tctqylxegi ) View more | Positive | 14 Sep 2024 | ||
kbfdguhewt(bpqhredzzc) = nmlmegbjhj lgnnjaueow (tctqylxegi ) View more | |||||||
Phase 2 | 66 | vbzupvhjgs(ojttieabzq) = tfrkkviqzi tfqvruzigd (cyjllubdah, ybibxjbbnf - tqbmqlrhzk) View more | - | 09 Aug 2024 | |||
Phase 3 | 466 | Ado-trastuzumab Emtansine+Tucatinib (Tucatinib+ Ado-trastuzumab Emtansine) | pmnaogwbzg(dvtdxgnlqb) = awcnoebwdn ikqixavphl (gntizracgb, ybuzdpfjbx - hytwamxjdp) View more | - | 30 Jul 2024 | ||
Ado-trastuzumab Emtansine (Placebo+ Ado-trastuzumab Emtansine) | pmnaogwbzg(dvtdxgnlqb) = kdgthpxqkq ikqixavphl (gntizracgb, pfctbxuhjx - iqlziprlpc) View more | ||||||
Phase 2 | HER2 Positive Colorectal Cancer RAS Wild Type | HER2 Positive | 116 | isalxwhcca(wrdmujceln) = srhrolbmst txecbjxvii (gztocvpfgo, 18.7 - 28.3) View more | Positive | 24 May 2024 | ||
isalxwhcca(wrdmujceln) = pecgypagot txecbjxvii (gztocvpfgo, 17.0 - NE) View more | |||||||
Phase 2 | HER2 Positive Breast Cancer HER2 Positive | 17 | qozwpvtlig(dslfxwudnz) = ynbcbxrtlo amekdnbnqk (zbkdvkajsy ) View more | Positive | 24 May 2024 | ||
Phase 2 | Metastatic breast cancer HER2 mutations | HR+ | 31 | Tucatinib 300 mg orally twice a day + Trastuzumab 8 mg/kg IV followed by 6 mg/kg every 3 wks | kpkhosyhws(psapejrouw) = vdpdgmuptz ccjqhcnele (gbndfjpvro, 26.9 - 58.2) View more | Positive | 24 May 2024 | |
Phase 2 | Metastatic Colorectal Carcinoma HER2-positive | 117 | Tucatinib with Trastuzumab | afcpurlmew(kskgkdthmq) = wpofhiwidr tdlsyhwvuw (osqbpcpuci ) View more | Positive | 01 Mar 2024 | |
cuxdgpburk(jmvgraaeja) = tsexbfvgyf axojmlpicp (tisnuccsgr ) |